The adverse effects of valproic acid on visual functions in the treatment of retinitis pigmentosa

Basit Öğe Kaydı
dc.contributor.authorTotan, Yüksel
dc.contributor.authorGüler, Emre
dc.contributor.authorYüce, Aslıhan
dc.contributor.authorDervişoğulları, Mehmet Serdar
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:56:23Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:56:23Z
dc.date.issued2017
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalı
dc.descriptionWOS: 000413741300015
dc.descriptionPubMed ID: 29044065
dc.description.abstractPurpose: To evaluate the efficacy and safety of valproic acid (VPA) treatment in patients with retinitis pigmentosa (RP). Methods: A total of 48 eyes of 24 patients (13 males, 11 females) with RP prescribed VPA were included. The length of VPA treatment was 6-12 months (mean 9.4 months). Parameters evaluated were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution [logMAR]), visual field analyses (VFAs) with Humprey automated perimetry, multifocal electroretinography (ERG) with Roland-RETI scan, and VPA side effects. Results: Mean age was 34.3 +/- 10.3 years (range 18-56 years). Fifteen of the patients (30 eyes) had two ERG and VFA tracings, allowing comparison between baseline and follow-up (range 6-12 months). Mean BCVA before and after VPA therapy was 0.36 +/- 0.38 and 0.36 +/- 0.37 logMAR, respectively (P = 0.32). Quantitative perimetric indices including mean deviation and pattern standard deviation were not significantly changed after VPA therapy (P > 0.05). P1 amplitudes (in terms of nV/deg(2) and mV) of ERG waves were significantly decreased in the rings 1, 3, and 4 after VPA therapy (P < 0.05). Regarding the N1 amplitudes, the only significant decrease was observed in area 1 (P = 0.03). In addition, N1 latency was significantly increased in area 3 after VPA therapy (P = 0.04). Conclusions: VPA therapy did not have any significant benefit on BCVA and VFA. In addition, it may be associated with decline in some ERG parameters. Therefore, physicians should avoid prescribing VPA for RP until its safety and efficacy are appropriately evaluated.
dc.identifier.citationTotan, Y., Güler, E., Yüce, A. ve Dervişoğulları, M. S. (2017). The adverse effects of valproic acid on visual functions in the treatment of retinitis pigmentosa. Indian Journal of Ophthalmology, 65(10), 984-988. https://dx.doi.org/10.4103/ijo.IJO_978_16
dc.identifier.doi10.4103/ijo.IJO_978_16
dc.identifier.endpage988
dc.identifier.issn0301-4738
dc.identifier.issn1998-3689
dc.identifier.issue10
dc.identifier.scopusqualityQ3
dc.identifier.startpage984
dc.identifier.urihttps://dx.doi.org/10.4103/ijo.IJO_978_16
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2689
dc.identifier.volume65
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMedknow Publications & Media Pvt Ltd
dc.relation.ispartofIndian Journal of Ophthalmologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 Unported*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/3.0/*
dc.subjectElectroretinogram
dc.subjectRetinitis Pigmentosa
dc.subjectValproic Acid
dc.subjectVisual Field
dc.titleThe adverse effects of valproic acid on visual functions in the treatment of retinitis pigmentosa
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
totan-yuksel(2017).pdf
Boyut:
766.27 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu